Remove Big Data Remove Development Remove Marketing Remove Pharma Companies
article thumbnail

What’s the next step in big data and AI?

Drug Discovery World

Big data and AI are all the rage. But, beyond these buzzwords and the quantity of data, what’s next for these powerful tools? His work provides insight into AI and big data in relation to pharma and drug discovery– now and in the future. Up front collection and controlling your data! Key opportunties.

article thumbnail

How digital innovation is helping therapeutics to get to market faster

Drug Discovery World

From finding potential active substances and identifying novel targets, to simulating how drugs will function in the human body and optimising laboratory workflows, digital technologies are having a significant impact on drug discovery and development. The company’s platform evaluated more than 11.4

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Meet the Researcher: Nicola McCarthy, Milner Therapeutics Institute

Drug Discovery World

NM: So, what we’re interested in the Milner is basically partnering between pharma and academia. We have a big consortium agreement that, at the moment, involves 14 pharma companies. It’s a way of pharma being able to dip their toes in new areas and de-risking from that point of view.

article thumbnail

Vodcast: Nicola McCarthy, Milner Therapeutics Institute, at SLAS 2024

Drug Discovery World

NM: So, what we’re interested in the Milner is basically partnering between pharma and academia. We have a big consortium agreement that, at the moment, involves 14 pharma companies. It’s a way of pharma being able to dip their toes in new areas and de-risking from that point of view.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Originator pharma companies are developing ever more complex products, which are transforming the medical landscape, but their cost places an increasing burden on healthcare budgets worldwide. It could also include specialty products that are harder to develop compared to standard generic products.

article thumbnail

A history of AstraZeneca

pharmaphorum

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.